Clinical Trials Logo

Microbiome clinical trials

View clinical trials related to Microbiome.

Filter by:

NCT ID: NCT04114513 Withdrawn - Metabolic Syndrome Clinical Trials

Dietary Fibers Effect on the Gut Microbiota Composition

Start date: November 25, 2019
Phase: N/A
Study type: Interventional

The randomized double-blinded placebo-controlled multicenter study will be held in parallel groups. During 5 weeks the efficacy of different endpoints as a measure of response to the daily intake of dietary fibers (8 g of either inulin, pectin, beta-glucan or galactooligosaccharides) will be evaluated. Gut microbiota composition, lipids levels, inflammation markers, microbiome metabolites, changes in quality of life and stool parameters will be assessed in order to predict individual response in participants without serious chronic diseases

NCT ID: NCT04100603 Recruiting - Clinical trials for Clostridium Difficile Infection

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection

Start date: March 2, 2020
Phase:
Study type: Observational

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

NCT ID: NCT04099446 Withdrawn - Melanoma (Skin) Clinical Trials

A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer

Start date: October 2019
Phase:
Study type: Observational

This study seeks to correlate microbial sequencing data from a punch biopsy in patients with skin cancer both melanoma and non-melanoma.

NCT ID: NCT04046822 Recruiting - Obesity Clinical Trials

Effect of Liraglutide on Microbiome in Obesity

Start date: January 9, 2019
Phase: Phase 4
Study type: Interventional

The purpose of the trial is to assess whether the beneficial effect of liraglutide on weight is mediated by changes in the composition of the intestinal Microbiome. The main mechanisms of action of liraglutide were traced to a reduction in the secretion of glucagon and slowing gastric emptying resulting in decreased appetite and body weight. It also seems that liraglutide is capable of increasing the satiety signals thanks to a dual mechanism of stimulation and inhibition induced by medication. Pomc neurons (opiomelacortin) present in hypothalamic arcuate nuclei, stimulated by liraglutide, glucagon-like peptide- 1 (GLP-1) receptor expressed by inhibiting intensely appetite. At the same time through the GABAergic neuronal activity is inhibited neuropeptide Y(NPY) deputies to the production of orexins that are powerful promoters of appetite. Alterations in the composition of the human gut microbiome occur in metabolic disorders such as obesity, diabetes. Liraglutide has been reported to switch microbiome composition towards lean-related bacterial phylotypes in animal studies. This leads to hypothesize that the switch of microbiome by liraglutide may be one of the mechanisms through which liraglutide may exert its effect. In particular the investigators hypothesize that liraglutide could restore a healthy microbiome or at least improve the microbiome composition through slowing gastrointestinal motility. Moreover, the liraglutide-related change of microbiome could be an additional mechanism that contribute to the beneficial metabolic effect of liraglutide. To test this hypothesis the investigators will investigate if there will be any change of gut microbiome assessed as Firmicutes-to-Bacteroidetes ratio after liraglutide treatment. In order to understand if the change of gut microbiome after liraglutide treatment occurs as an association or contributes to the effect of liraglutide ,the investigators will correlate the Firmicutes-to-Bacteroidetes ratios with the changes of Body Mass Index, Body Composition, appetite parameters, chronic inflammation parameters, lipid profile and insulin resistance. All the subjects will follow the same diet in order to avoid any bias.

NCT ID: NCT03934021 Recruiting - Stroke Clinical Trials

Gut Microbiota in Acute Stroke Patients

Start date: July 1, 2018
Phase:
Study type: Observational

This study is to find out the significance of gut-microbiota in acute stroke patients, including their neurological, radiological outcomes as well as their stroke mechanisms.

NCT ID: NCT03819179 Completed - Microbiome Clinical Trials

The Influence of Personal Care Products on the Skin Microbiome

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

To evaluate whether personal care products shift the skin microbiome bacteria and diversity after a week of daily use.

NCT ID: NCT03718988 Completed - Clinical trials for Cardiovascular Diseases

SWAP-MEAT: Study With Appetizing Plant Food - Meat Eating Alternatives Trial

SWAP-MEAT
Start date: January 17, 2019
Phase: N/A
Study type: Interventional

This study aims to investigate the impact of replacing meat consumption with plant-based meat alternative consumption on cardiovascular health, the gut microbiome, and metabolic status.

NCT ID: NCT03710850 Completed - Insulin Resistance Clinical Trials

Modification of Gut Microbiota in the Treatment of Insulin Resistance: a Personalized Approach

TRIEMA
Start date: May 1, 2018
Phase: N/A
Study type: Interventional

Gut microbiota may play a key role in many metabolic diseases, including type 2 diabetes (T2D). Consumption of high-fat/high-sugar western diet seem to alter human resident microbiota towards reduced genetic diversity and to influence its metabolic activity towards enhanced energy extraction. Plant-based diets are effective in the treatment of T2D but it is not clear whether their effect results solely from diet composition or whether it is mediated, at least partly, by different microbiota and its metabolic activity. One possible therapeutic approach is replacement of "pro-diabetic" microbiota with its "healthy" variant but what the "healthy" microbiota is and under which conditions this microbiota could stay stable and functional is not known. The aim of the proposed study is to identify possible metagenome/metabolome characteristics in different human cohorts (T2D vs vegans), to assess the stability of vegan microbiota in T2D-like environment and to evaluate the possibility to influence human T2D microbiota/metabolome towards more protective composition by dietary intervention.

NCT ID: NCT03690999 Completed - Inflammation Clinical Trials

The RAMP Study - Rejuvenation of the Aging Microbiota With Prebiotics

RAMP
Start date: March 14, 2019
Phase: N/A
Study type: Interventional

An individual's immune and metabolic status is coupled to consumed carbohydrates. Complex carbohydrates that are not digested by human enzymes may influence host biology by impacting microbiota composition and function, or act in a yet-unknown microbiota-independent manner. Prebiotics offer a promising safe route to influence host health, possibly via the microbiota. However, it remains largely unknown to what extent immune function and metabolism can be modulated by prebiotics.

NCT ID: NCT03647449 Completed - Microbiome Clinical Trials

Examining the Effects of Juice Fasting

Start date: July 10, 2018
Phase: N/A
Study type: Interventional

This study tests the effectiveness of dietary interventions that have the possibility to improve markers of gut health and improve general well-being. This study will allow healthcare professionals to learn how dietary interventions involving fasting can affect health. Food is increasingly recognized as a core component of preventive and ameliorative health care. Juice fasting has quickly become one of the most popular self-prescribed dietary interventions in the United States. A wide variety of juice fasts are available in the popular market; a popular variation is the three-day juice fast. The purpose of this study is to assess the effects of a three-day juice fast on certain markers of age-related disease and bio-markers of longevity. In particular, this study will assess certain epigenetic markers, which measure how the environment (including diet) can change the way that genes are expressed without changing the genes themselves. The study will also assess the microbiome, and inflammatory and glycemic markers.